Antibody · 위암 · PD-1 / PD-L1

3개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved3 programs
AntibodyCurated CoreFDABeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
AntibodyLimited DatastaleShanghai Kechow Pharma, Inc.Phase 2

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#GastricAdenocarcinoma+1
Trials 2Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tucidinostat (Tucidinostat, Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, chidamide)

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#EsophagealSquamousCellCancer+3
Trials 1Status Active